PuriCore Announces Clinical Results for Vashe Wound Therapy in Post-Operative Care of Skin Grafts on Burns

PuriCore announces results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries. Vashe Wound Therapy is a medical device that produces a biocompatible solution to enhance the clinical management of acute and chronic wounds and has been used successfully and without report of adverse events in more than 100,000 wound treatments. It is designed to be a safe, effective and economical alternative to commonly used wound irrigating solutions that inhibit wound healing.

The clinical trial was conducted by Kevin Foster, MD, MBA, FACS, co-director of the Arizona Burn Center at the Maricopa Medical Center in Phoenix. Results showed that Vashe Wound Therapy is as effective as the control, 5 percent Sulfamylon® solution (mafenide acetate, USP), a synthetic antimicrobial agent, in the post-operative care of grafts for burns and potentially provides greater pain control.

The average graft take for Vashe Wound Therapy and 5 percent Sulfamylon was 97.4 percent and 96 percent, respectively. Infection rates during the trial were equivalent, and none were attributable to the therapy. Further, the trial showed that Vashe Wound Therapy demonstrated greater than a 50 percent cost-savings compared with 5 percent Sulfamylon. Foster presented results of this trial at the Southern Regional Burn Conference on Nov. 7 in Shreveport, La.

"Vashe Wound Therapy is an exciting new alternative technology that demonstrates clinical efficacy for post operative skin graft irrigation while offering significant overall cost savings,” said Foster. “This trial also suggests that Vashe has further potential for pain improvement opportunities."

“These clinical results are further evidence that Vashe Wound Therapy is highly effective for wound care, offering an additional boost to the bodys own defense and without any cytotoxic effects that can slow the rate of wound healing,” said PuriCore CEO Greg Bosch. “With the increasing attention to cost-containment in healthcare, Vashe Wound Therapy offers a new cost-effective alternative to traditional wound irrigants.”

Vashe Wound Therapy is a medical device used for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, postsurgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. Vashe Wound Therapy is biocompatible, non-cytotoxic, and non-mutagenic. Research to date demonstrates that the Vashe Solution provides a safe and effective alternative to cytotoxic products currently used to treat infected wounds and post-operative surgical sites and is an important element in the overall plan of care for effective wound management. It is a cost-effective alternative to traditional wound irrigants and is a nonstaining solution.

PuriCore is a life sciences company focused on developing and commercializing proprietary green solutions that safely, effectively and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore’s patented, proprietary technology mimics the human body’s production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitization.

 

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish